Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Recent technical advances in peripheral blood analysis have enabled precise quantification of Alzheimer´s Disease (AD) biomarkers in the early stages of the AD continuum, in an economical, non-invasive and safe manner.
Why it matters
This study measured blood biomarkers including p-tau217, p-tau181, total tau, neurofilament light, and the amyloid-β 42/40 ratio, along with brain imaging, to characterize early stages of cognitive impairment. It is a characterization study and does not test any treatment, cure, or prevention.
-
Alzheimer's disease (AD), the most common cause of dementia, is characterized by the accumulation of amyloid-β (Aβ) in senile plaques and abnormally hyperphosphorylated tau proteins in neurofibrillary tangles.
Why it matters
This review summarizes evidence that APOE ε4 worsens tau-mediated neurodegeneration and tau-related pathology, in addition to promoting amyloid deposition. It suggests the apoE-tau interaction as a possible therapeutic target, but it is a review of existing knowledge and reports no tested treatment.
-
In this study, we show that repeated ethanol binges aggravate the amyloid pathology and plaque burden in the hippocampus of APP/PS1 mice.
Why it matters
In mice with Alzheimer's-like pathology, repeated heavy drinking increased amyloid plaques and brain inflammation. This suggests that heavy alcohol use may worsen Alzheimer's-related brain changes, though the findings come from animal models.
-
This study reveals key sex differences in ADIA patients.
Why it matters
In this study of Alzheimer's dementia patients with irritability and anger, men were more likely to have hypertension, insomnia, dyslipidemia, and peripheral vascular disease, while women were more likely to have osteoporosis, gait dysfunction, anxiety, urinary tract infection, and headaches. These findings point to different risk factor profiles by sex, which could inform how irritability and anger are managed in Alzheimer's patients.
-
On continuous scales, lipoprotein(a) levels were not associated with the risk of Alzheimer's disease or vascular-related dementia.
Why it matters
Across three cohort studies, lipoprotein(a) levels were not associated with the risk of Alzheimer's disease or vascular-related dementia on continuous scales. The authors state it cannot be excluded that very high lipoprotein(a) or small isoform size increases dementia risk.
-
The results project substantial cost savings from implementing a blood test for AD pathology within the diagnostic pathway based on modeling results, which future research should confirm with actual data.
Why it matters
This modelling study estimated the value-based price of a blood test for Alzheimer's disease pathology with sensitivity of 88% and specificity of 89%, finding prices of $290 for triage and $1150 for confirmation in primary care, and $450 and $1950 in specialty care. It concerns the economic value of a diagnostic test rather than treating, curing, or preventing Alzheimer's disease.
-
Alzheimer's disease is a neurodegenerative disorder characterized by two hallmarks: amyloid beta plaques and neurofibrillary tangles.
Why it matters
This is a computer-based (in-silico) study that screened many compounds and identified one, Hit-6, as a possible RAGE inhibitor worth further study. No laboratory or human testing was done, so it does not yet show any treatment or prevention benefit for Alzheimer's disease.
-
Alzheimer's disease (AD) is characterized by the pathological accumulation of amyloid plaques and hyperphosphorylated tau proteins, leading to disruptions in synaptic transmission and neural circuit alterations.
Why it matters
This review describes quantitative EEG biomarkers, including decreased alpha power and increased theta power correlating with Alzheimer's disease severity, as tools for diagnosis and monitoring. It presents no treatment, cure or prevention.
-
Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4).
Why it matters
Combining amyloid and FDG PET improved prediction of short-term conversion from mild cognitive impairment to Alzheimer's disease, with faster conversion in those positive on both scans. This is a prognostic finding and does not test any treatment or prevention.
-
Alzheimer's disease (AD) and frontotemporal dementia (FTD) are the most common forms of dementia globally.
Why it matters
This review examines microRNAs as promising novel biomarkers for Alzheimer's disease and frontotemporal dementia, emphasizing their potential as accessible, noninvasive tools for diagnosing these disorders. No diagnostic or treatment application is yet established.
-
BackgroundC1q is a promoter of the classical pathway of complement and its massive expression may be associated with the development of Alzheimer's disease (AD).
Why it matters
In this study of 1264 cognitively intact adults, plasma C1q levels were examined in relation to cerebrospinal fluid amyloid and tau biomarkers across preclinical stages. It is an association study and does not report any treatment, cure, or prevention.
-
Three factors (psychosis, agitation, and affective disturbance) were extracted for AD.
Why it matters
This neuroimaging study found that three neuropsychiatric syndromes - psychosis, agitation, and affective disturbance - may heterogeneously associate with Alzheimer's disease, dementia with Lewy bodies, and mild cognitive impairment. It does not test any treatment, so it does not show a cure or prevention.
-
Early NPS burden as well as NPS severity progression rate, independently of cognitive status, might be useful clinical metrics and may help predict underlying pathological diagnoses.
Why it matters
This study found that neuropsychiatric symptoms increase over time in Alzheimer's disease and dementia with Lewy bodies, with the rate of change greater in DLB, and that initial scores were highest in AD with Lewy bodies. It describes symptom trajectories but does not provide a treatment or cure.
-
45/100
Plasma Aβ 42/40 , p‐tau‐181, and NfL differ in those with CAA and together can discriminate CAA from healthy controls.
Why it matters
In 45 people with CAA and 47 healthy controls, a combination of plasma Aβ 42/40, p-tau-181 and NfL distinguished CAA from controls with an area under the curve of 0.90. This is a diagnostic finding only and does not address treating, curing or preventing Alzheimer's disease.
-
Using the RGC marker ribonucleic acid binding protein with multiple splicing (RBPMS) and Nissl staining, we found a 46–56% reduction in RBPMS + RGCs and Nissl + neurons in the ganglion cell layer (GCL) of MCI and AD retinas ( P < 0.05–0.001).
Why it matters
Retinas from people with mild cognitive impairment or Alzheimer's dementia showed loss of retinal ganglion cells along with accumulation of phosphorylated and oligomeric tau. This describes what happens in eye tissue during the disease but does not test any treatment, cure, or prevention.
-
BackgroundThe clinical significance of enlarged perivascular spaces (EPVS) in Alzheimer' s disease (AD) was ambiguous.
Why it matters
In this study of 64 participants, high-grade enlarged perivascular spaces in the centrum semiovale were associated with Alzheimer's disease and with lower cognition, and they correlated with blood-brain barrier leakage. These findings describe a relationship between vascular and barrier changes and cognition, but they do not test any treatment, cure, or prevention.
-
In 2021, the ASRs for AD and other dementias incidence and prevalence in Vietnam were 110.09 (95 % UI: 96.21-126.57) and 649.42 (95 % UI: 556.89-744.39) per 100,000 persons which were comparable to those in the Southeast Asia region and globally, with the burden predominantly observed in individuals aged 65 and older.
Why it matters
This analysis of Vietnam data from 1990 to 2021 found that while incidence and prevalence of Alzheimer's disease and other dementias declined, disability-adjusted life years and mortality rates increased significantly. High fasting plasma glucose, elevated body mass index, and smoking were identified as the most significant risk factors.
-
45/100
This well-characterized case of PCA syndrome due to AD in a very young patient with DS demonstrates the occurrence of atypical presentations in DS that might be overshadowed by the baseline intellectual disability associated with DS.
Why it matters
This single case describes a 39-year-old man with Down syndrome who developed posterior cortical atrophy due to Alzheimer's disease, an atypical presentation. It shows that unusual Alzheimer's presentations can occur in Down syndrome and may be missed because of baseline intellectual disability, but as one case report it does not test any treatment.
-
The SARS-CoV-2 pandemic accelerated development of innovative methods for conducting research remotely via digital technologies.
Why it matters
Among adults enrolled in Alzheimer's research, cognitive impairment, race, and neighborhood disadvantage were linked to lower digital access and skill. This matters for who can take part in remote research assessments, not for treating or preventing the disease itself.
-
45/100
The average age at LP was 79.3 years (SD = 5.6), and the average age at death was 87.1 years (SD = 6.5).
Why it matters
This study found that CSF p-tau181/Aβ42 measured with Lumipulse was strongly associated with postmortem amyloid plaque and tangle staging. It is a biomarker validation study and does not provide any treatment, cure, or prevention for Alzheimer's disease.
-
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has fostered collaboration among researchers around the world, catalyzing innovation and accelerating progress in the field.
Why it matters
This paper describes how the Argentina-Alzheimer's Disease Neuroimaging Initiative helped develop and validate Alzheimer's biomarkers in Latin America and led to multinational studies on prevention, diagnosis and treatment. It is about building regional research capacity and informing health policy, not about testing a specific therapy.
-
45/100
The most prevalent cause of dementia is Alzheimer's disease.
-
Prostate cancer (PCa) is one of the most prevalent malignancies affecting males worldwide.
-
Alzheimer is an irreversible progressive neurodegenerative disease that causes failure of cerebral neurons and disability of the affected person to practice normal daily life activities.
Why it matters
This review states there is no concrete evidence identifying the exact cause of Alzheimer's disease, so several hypotheses have emerged pointing to many possible therapeutic targets. It notes that an extensive number of drugs have been studied in clinical trials, but only galantamine, donepezil and rivastigmine are mentioned as reaching use.
-
Tau spatial spread may demonstrate earlier changes than tau burden which could have broad impact in clinical trial design.
Why it matters
In 445 participants across early Alzheimer's disease stages, both tau burden and a new measure of tau spatial spread were elevated with disease stage, and tau spatial spread may change earlier than tau burden. This is a cross-sectional imaging biomarker study and does not test any treatment, cure or prevention.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Explorando a inibição da bace: uma revisão sistemática dos potenciais tratamentos para a doença de Alzheimer
- Reactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer's disease
- Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings
- Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging
- A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease
- Association Between Alzheimer Pathology, Sleep, and Cognition in Patients With Late-Onset Unexplained Epilepsy
- A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging
- Stroke and the risk of Alzheimer disease
- Fluid biomarkers in Alzheimer's disease - current concepts
- Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease